2 transcripts
VKTX
Earnings call transcript
NASDAQ
2023 Q4
7 Feb 24
men and women and demonstrated that single subcutaneous doses of VK2735 were safe and well tolerated and displayed favorable pharmacokinetics. VK2735
VKTX
Earnings call transcript
NASDAQ
2023 Q2
26 Jul 23
and encouraging signs of clinical benefit.
The single ascending dose portion of this study enrolled healthy men and women and evaluated escalating
- Prev
- 1
- Next